Methotrexate in psoriatic arthritis

Bulletin of the Hospital for Joint Diseases

Volumn 71, Issue , 2013, Pages S41-S45

  Mease, Philip ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CHOLESTATIC HEPATITIS; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; DACTYLITIS; DRUG EFFICACY; ENTHESITIS; GASTROINTESTINAL DISEASE; HUMAN; LIVER TOXICITY; PSORIATIC ARTHRITIS; REMISSION; SPONDYLITIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; HUMANS; METHOTREXATE; TREATMENT OUTCOME;

EID: 84888349337     PISSN: 23284633     EISSN: 23285273     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005 Oct;53(4):573.
2. Mease P, Gladman D, Papp K, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013 Aug 24. pii:S0190-9622(13):007779.
3. Wright V. Psoriatic arthritis; a comparative study of rheumatoid arthritis, psoriasis, and arthritis associated with psoriasis. AMA Arch Derm. 1959 Jul;80(1):27-35.
4. Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo-and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther. 2005;7(3):R569-80.
5. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011 Mar;70 (Supp 1):i77-84.
6. Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009 Jan-Feb;22(1):40-55.
7. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-73.
8. Helliwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs --comparison of drugs and adverse reactions. J Rheumatol. 2008 Mar;35(3):472-6.
9. Kane D, Gogarty M, O’Leary J, et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum. 2004 Oct;50(10):3286-95.
10. Black RL, O’Brien WM, Vanscott EJ, et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA. 1964 Sep 7;189:743-7.
11. Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984 Apr;27(4):376-81.
12. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012 Aug;51(8):1368-77.
13. Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012 Apr;71(4):541-8.
14. Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S132-7.
15. Lie E, van der Heijde D, Uhlig T, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Apr;69(4):671-6.
16. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol. 2008 Mar;35(3):469-71.
17. Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol. 1995 Feb;22:241-5.
18. Mease PJ. Psoriatic arthritis and spondyloarthritis assessment and management update. Curr Opin Rheumatol. 2013 May;25(3):287-96.
19. Burmester G, Kivitz A, Kupper H, et al. Efficacy, pharmacokinetics, and safety of different doses of methotrexate in combination with adalimumab: results from the CONCERTO trial. Ann Rheum Dis. 2013;OP0067(EULAR):abstract.
20. Chen J, Veras MM, Liu C, et al. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2013;Feb 28(2):CD004524.
21. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008 Mar;158(3):558-66.
22. Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011 Oct;365(17):1586-96.
23. Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderateto-severe plaque psoriasis: results of an open-label, activecontrolled, randomized trial (RESTORE1). Br J Dermatol. 2011 Nov;165(5):1109-17.
24. Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991 Jun;90(6):711-6.
25. Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010 Jan;69(1):43-7.
26. Kavanaugh A, Greenberg J, Lee S, et al. Incidence of elevated liver enzymes (LFTs) in psoriatic arthritis (PsA) patients: effect of TNF-inhibitors (TNF-I). Ann Rheum Dis. 2010;SAT0282(EULAR):abstract.